Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader with immunomodulatory drug (IMiD) activity for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader without IMiD activity for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; DeTIL-0255 for tumor infiltrating lymphocytes therapy; KINASE-CTM3 to treat T cell malignancies and autoimmune diseases; and LIGASE-INH2 for immuno-oncology. In addition, the company develops programs, such as COVID-CTM1, COVID-CTM2, and COVID-CTM3 that are designed for protein degradation to SARs CoV2 targets. Nurix Therapeutics, Inc. has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.
IPO Year: 2020
Exchange: NASDAQ
Website: nurixtx.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
9/6/2024 | $26.00 | Outperform | Robert W. Baird |
7/31/2024 | $36.00 | Buy | Truist |
6/26/2023 | $25.00 | Outperform | Oppenheimer |
3/9/2023 | $20.00 | Overweight | Barclays |
2/28/2023 | $25.00 | Outperform | Oppenheimer |
10/11/2022 | $11.00 | Equal-Weight | Morgan Stanley |
5/31/2022 | $25.00 | Equal Weight → Overweight | Wells Fargo |
2/10/2022 | $28.00 | Equal-Weight | Wells Fargo |
12/29/2021 | $62.00 | Buy | HC Wainwright & Co. |
10/27/2021 | $50.00 → $64.00 | Outperform | SVB Leerink |
SC 13G/A - Nurix Therapeutics, Inc. (0001549595) (Subject)
SC 13G/A - Nurix Therapeutics, Inc. (0001549595) (Subject)
SC 13G/A - Nurix Therapeutics, Inc. (0001549595) (Subject)
SC 13G/A - Nurix Therapeutics, Inc. (0001549595) (Subject)
SC 13G/A - Nurix Therapeutics, Inc. (0001549595) (Subject)
SC 13G - Nurix Therapeutics, Inc. (0001549595) (Subject)
SC 13G - Nurix Therapeutics, Inc. (0001549595) (Subject)
SC 13G/A - Nurix Therapeutics, Inc. (0001549595) (Subject)
SC 13G - Nurix Therapeutics, Inc. (0001549595) (Subject)
SC 13G - Nurix Therapeutics, Inc. (0001549595) (Subject)
4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
Nurix Therapeutics (NASDAQ:NRIX) has been analyzed by 12 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 5 7 0 0 0 Last 30D 0 2 0 0 0 1M Ago 3 3 0 0 0 2M Ago 0 1 0 0 0 3M Ago 2 1 0 0 0 Analysts have set 12-month price targets for Nurix Therapeutics, revealing an average target of $29.0, a high estimate of $35.00, and a low estimate of $20.00. Observing a 4.69% increase, the current
JP Morgan analyst Eric Joseph maintains Nurix Therapeutics (NASDAQ:NRIX) with a Overweight and raises the price target from $31 to $34.
Barclays analyst Peter Lawson maintains Nurix Therapeutics (NASDAQ:NRIX) with a Overweight and raises the price target from $20 to $31.
RBC Capital analyst Gregory Renza maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and raises the price target from $26 to $27.
Needham analyst Gil Blum maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and lowers the price target from $31 to $29.
Cash, cash equivalents and marketable securities was $452.5 million as of May 31, 2024, compared to $254.3 million as of February 29, 2024.
Nurix Therapeutics (NASDAQ:NRIX) reported quarterly losses of $(0.71) per share which missed the analyst consensus estimate of $(0.63) by 12.7 percent. This is a 57.78 percent decrease over losses of $(0.45) per share from the same period last year. The company reported quarterly sales of $12.092 million which missed the analyst consensus estimate of $22.105 million by 45.30 percent. This is a 60.58 percent decrease over sales of $30.676 million the same period last year.
In the last three months, 14 analysts have published ratings on Nurix Therapeutics (NASDAQ:NRIX), offering a diverse range of perspectives from bullish to bearish. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 8 6 0 0 0 Last 30D 0 1 0 0 0 1M Ago 2 2 0 0 0 2M Ago 2 1 0 0 0 3M Ago 4 2 0 0 0 In the assessment of 12-month price targets, analysts unveil insights for Nurix Therapeutics, presenting an average target of $28.5, a high estimate of $35.00, and a low estimate of $20.00. Witnessing a posit
RBC Capital analyst Gregory Renza maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and raises the price target from $23 to $26.
SAN FRANCISCO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced three oral presentations at the 22nd Annual Discovery on Target conference, being held September 30 – October 3, 2024, in Boston, MA. "The presentations at Discovery on Target highlight Nurix's ability to repeatedly address difficult-to-drug target classes including E3 ligases and transcription factors using our DELigase platform," said Gwenn M. Hansen, Ph.D., chief scientific officer of Nurix. "In addition, we are continuing to expa
USA News Group Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Sept. 24, 2024 /PRNewswire/ -- USA News Group – Optimism is on the rise in fight against cancer, as researchers are making progress across the field of oncology. Helping to spur on the momentum, philanthropists recently gave a historic $150 million for pancreatic cancer research to City of Hope, while Stanford experts are calling for more massive federal funding increases to cancer research. According to the latest Cancer Progress Report from the American Association for Cancer Research, the USA has seen a 33% reduction in the overall cancer death rate from 1991 to 2021. Working behind the scenes are several
SAN FRANCISCO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Gwenn M. Hansen, Ph.D., chief scientific officer of Nurix, will present an update on Nurix's Degrader-Antibody Conjugate (DAC) platform at the ADC & Radiopharmaceuticals Pharma & Biotech Partnering Summit being held in Boston from September 9-10, 2024. Title: Targeted Protein Degraders As Next Generation Antibody Payloads Conference: ADC & Radiopharmaceuticals Pharma & Biotech Partnering SummitDate and time: Tuesday, September 1
SAN FRANCISCO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Arthur T. Sands, M.D, Ph.D., president and chief executive officer of Nurix, Hans van Houte, chief financial officer of Nurix, and Jason Kantor, Ph.D., chief business officer of Nurix, will participate in the following conferences in September: 2024 Wells Fargo Healthcare Conference (Boston, MA) Fireside chat: Thursday, September 5, 2024, from 4:30 – 5:05 p.m. ETH.C. Wainwright 26th Annual Global Investment Conference (New York C
Presented positive clinical data at the European Hematology Association Congress supporting a potential best-in-class profile for NX-5948 for the treatment of CLL Strengthened leadership with appointment of Paula G. O'Connor, M.D., as chief medical officer and Pasit Phiasivongsa, Ph.D., as chief technical officer Strengthened financial position ending the quarter with cash and marketable securities of $452.5 million SAN FRANCISCO, July 11, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today reported financial
SAN FRANCISCO, July 08, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, will participate in a fireside chat at the UBS Virtual Targeted Protein Degradation (TPD) Day, at 2:30 p.m. ET on Monday, July 15, 2024. The event will be webcast live and may be accessed via a link in the Investors section of the Nurix website under Events and Presentations. The archived webcast will be available for 30 days after the event. About Nur
USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 20, 2024 /PRNewswire/ -- USA News Group News Commentary – The potential threat of cancer looms for everyone, but now new studies are revealing an increased number of cancer cases in younger age groups than before. While researchers continue to search for a reason why this is happening, some are pointing towards increased rates of obesity, among other potential reasons. With the Global Oncology Drugs Market set to grow by 11.5% CAGR through 2033 to US$564.5 billion, according to Spherical Insights, the need for more effective therapies is becoming more apparent. The biotech sector continues to work d
Objective response rate of 69.2% observed in heavily pretreated patient population including patients with BTK inhibitor resistance mutations Clinical responses in CLL patients were rapid and deepening with longer time on treatment Nurix intends to advance NX-5948 into pivotal trial(s) in 2025 Company will host a webcast conference today, June 16, 2024, at 9:00 a.m. ET (3:00 p.m. CEST) SAN FRANCISCO, June 16, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced the presentation of updated clinical d
SAN FRANCISCO, June 10, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that the company will host a webcast and conference call at 9:00 a.m., ET, on Sunday, June 16, 2024, to discuss data from the ongoing Phase 1 clinical trial of NX-5948 that will be presented in an oral session at the European Hematology Association Congress in Madrid, Spain. The oral presentation at EHA2024 will summarize updated data from the ongoing Phase 1a/b study of NX-5948 in heavily pretreated patients with relapsed/refractor
SAN FRANCISCO, May 29, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, will present a corporate update at the Jefferies Global Healthcare Conference, at 5:30 p.m. ET on Wednesday, June 5, 2024, in New York City. The event will be webcast live and may be accessed via a link in the Investors section of the Nurix website under Events and Presentations. The archived webcast will be available for 30 days after the event. About
Objective response rate of 69.2% observed in heavily pretreated patient population including patients with BTK inhibitor resistance mutations Clinical responses in CLL patients were rapid and deepening with longer time on treatment Nurix intends to advance NX-5948 into pivotal trial(s) in 2025 Company will host a webcast conference today, June 16, 2024, at 9:00 a.m. ET (3:00 p.m. CEST) SAN FRANCISCO, June 16, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced the presentation of updated clinical d
SAN FRANCISCO, June 10, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that the company will host a webcast and conference call at 9:00 a.m., ET, on Sunday, June 16, 2024, to discuss data from the ongoing Phase 1 clinical trial of NX-5948 that will be presented in an oral session at the European Hematology Association Congress in Madrid, Spain. The oral presentation at EHA2024 will summarize updated data from the ongoing Phase 1a/b study of NX-5948 in heavily pretreated patients with relapsed/refractor
Overall response rate of 70% observed in 10 evaluable heavily pretreated CLL patients Data showcase deepening clinical responses with longer time on therapy in CLL patients including patients with resistance mutations to BTK inhibitors The oral presentation at EHA will include additional data at higher dose levels and longer treatment durations Company will host a webcast conference call on June 16 following the data presentation at EHA (details to follow) SAN FRANCISCO, May 14, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory
Nurix and Seagen to develop a portfolio of Degrader-Antibody Conjugates (DACs): antibodies that deliver a targeted protein degrader payload to selectively kill cancer cells Nurix to receive a $60 million upfront payment, in addition to the potential for approximately $3.4 billion in milestone payments plus future royalties Nurix retains an option for U.S. profit sharing and co-promotion on two products arising from the collaboration Nurix to host a conference call today, September 7 at 8:30 a.m. ET SAN FRANCISCO, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to
Robust BTK target degradation achieved in all patients treated to date Greater than 90% degradation of BTK was achieved at the 200 mg dose of NX-2127 These data represent the first proof of mechanism of targeted protein degradation in patients with hematologic malignancies Nurix to host a conference call today at 8:30 a.m. ET SAN FRANCISCO, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced initial data demonstrating clinically meaningful degradation of Bruton's tyrosine kinase (BTK) in patients with relapsed or refractory B cell malignancies, including in a chronic lympho
Presentation to include initial pharmacokinetic and BTK degradation data Company to host conference call at 8:30 a.m. ET on Wednesday, October 27, 2021 SAN FRANCISCO, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that the Company will present initial pharmacokinetic and pharmacodynamic data from its first-in-human, Phase 1 dose-escalation trial of NX-2127 in adults with relapsed or refractory B-cell malignancies at the 4th Annual Targeted Protein Degradation Summit. The presentation will begin at 11:45 a.m. ET on Wednesday, October 27, 2021, and will be given by Nurix pr
8-K - Nurix Therapeutics, Inc. (0001549595) (Filer)
424B5 - Nurix Therapeutics, Inc. (0001549595) (Filer)
10-Q - Nurix Therapeutics, Inc. (0001549595) (Filer)
8-K - Nurix Therapeutics, Inc. (0001549595) (Filer)
8-K - Nurix Therapeutics, Inc. (0001549595) (Filer)
S-3ASR - Nurix Therapeutics, Inc. (0001549595) (Filer)
8-K - Nurix Therapeutics, Inc. (0001549595) (Filer)
8-K - Nurix Therapeutics, Inc. (0001549595) (Filer)
424B5 - Nurix Therapeutics, Inc. (0001549595) (Filer)
424B5 - Nurix Therapeutics, Inc. (0001549595) (Filer)
SAN FRANCISCO, May 28, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced the appointments of Paula G. O'Connor, M.D., as chief medical officer and Pasit Phiasivongsa, Ph.D., as chief technical officer of Nurix. "I am delighted to announce the promotions of both Paula and Pasit, which recognize their significant and ongoing leadership in advancing our pipeline of novel medicines and particularly in accelerating our NX-5948 program in chronic lymphocytic leukemia and non-Hodgkin's lymphoma," said Arthur T. Sa
Nurix leads targeted protein modulation field with its wholly owned clinical stage programs and two strategic collaborations fueled by its DELigase platform Clinical data updates planned for Nurix's two first-in-class BTK degraders in 2023 Clinical data update planned for Nurix's first-in-class CBL-B inhibitor in 2023 Significant progress made across deep pipeline of preclinical candidates SAN FRANCISCO, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today outlined key objectives and anticipated mil
Completed two registered direct offerings in July raising gross proceeds of $95 million Maintained strong financial position with $413.6 million in cash and marketable securities as of August 31, 2022 Expanded leadership team and board of directors with experienced industry leaders Announced multiple presentations at upcoming SITC 2022 annual meeting, including initial PK/PD data for NX-1607 program SAN FRANCISCO, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs, today reported financial results for the third quarter ended August 31, 2022 and provided a corporate update. "
SAN FRANCISCO, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, today announced the appointment of Edward C. Saltzman to its board of directors. Mr. Saltzman has over 30 years of drug strategic development experience in the biopharmaceutical and biotechnology industries, and currently serves as Head of Biotech Strategy at Lumanity Inc., a global pharmaceutical and biotechnology advisory firm. "I am delighted to welcome Ed to the Nurix board of directors at this important stage in the Company's growth as we advance multiple programs through clinical trials with significant p
SAN FRANCISCO, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, today announced that Eric Schlezinger, J.D. has joined the company as chief people officer. Mr. Schlezinger is an industry veteran with extensive experience leading and developing human resources at high-growth private and public biopharma companies. "Eric is a proven leader in building and maintaining exceptional company cultures and has an impressive track record in recruiting and retaining top talent in growing biopharmaceutical companies," said Arthur T. Sands, M.D., Ph.D., president and chief executive office
Initiated Phase 1 trial of lead CBL-B E3 ligase inhibitor program NX-1607 in patients with cancer Expanded Board of Directors with experienced business leaders Strong financial position with $465.4 million as of August 31, 2021 SAN FRANCISCO, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today reported financial results for the third quarter ended August 31, 2021 and provided a corporate update. "With the recent initiation of a Phase 1 trial for our lead E3 ligase inhibitor program NX-1607, we now have two wholly owned drug candidates in clinical development, both potentially addressin
Initiated Phase 1 trial of lead program NX-2127 in patients with relapsed or refractory B-cell malignancies On track to initiate Phase 1 trials for three additional wholly owned drug candidates in 2021 Strong financial position with $496 million as of May 31, 2021 SAN FRANCISCO, July 13, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics Inc. (NASDAQ:NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today reported financial results for the second quarter ended May 31, 2021 and provided a corporate update. "Our first clinical trial to evaluate NX-2127, an orally bioavailable degrader of Bruton's tyrosine kinase with immunomodulatory drug activity in patie
SAN FRANCISCO, June 01, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced the appointment of Clay Siegall, Ph.D., to its board of directors. Dr. Siegall is a co-founder of Seagen Inc. (formerly Seattle Genetics, Inc.) and serves as its president, chief executive officer, and chairman of the board. "As an experienced industry leader with a remarkable track record of success in building Seagen from a drug discovery platform company to a commercial-stage oncology company with multiple products, Clay brings a wealth of experience that will be extremely valuable as we enter the next phase o
Robert W. Baird resumed coverage of Nurix Therapeutics with a rating of Outperform and set a new price target of $26.00
Truist initiated coverage of Nurix Therapeutics with a rating of Buy and set a new price target of $36.00
Oppenheimer resumed coverage of Nurix Therapeutics with a rating of Outperform and set a new price target of $25.00
Barclays initiated coverage of Nurix Therapeutics with a rating of Overweight and set a new price target of $20.00
Oppenheimer initiated coverage of Nurix Therapeutics with a rating of Outperform and set a new price target of $25.00
Morgan Stanley initiated coverage of Nurix Therapeutics with a rating of Equal-Weight and set a new price target of $11.00
Wells Fargo upgraded Nurix Therapeutics from Equal Weight to Overweight and set a new price target of $25.00
Wells Fargo initiated coverage of Nurix Therapeutics with a rating of Equal-Weight and set a new price target of $28.00
HC Wainwright & Co. initiated coverage of Nurix Therapeutics with a rating of Buy and set a new price target of $62.00
SVB Leerink reiterated coverage of Nurix Therapeutics with a rating of Outperform and set a new price target of $64.00 from $50.00 previously